Baseimmune moves into new lab space at LBIC’s Apex Building in London’s Kings Cross to advance its AI platform for vaccine discovery. The company, co-founded and led by CEO Joshua Blight, focuses on developing vaccines for COVID and malaria. Its platform builds on lessons learned from global vaccine efforts during the pandemic.
Baseimmune Ltd secures fully fitted grow-on lab space at London Bioscience Innovation Centre (LBIC) within the Apex Building in Tribeca. The agreement supports the company’s vaccine development operations, leveraging LBIC’s infrastructure for biotech innovation. LBIC provides tailored lab facilities to accelerate early-stage biotech ventures.
Baseimmune develops AI-driven vaccines targeting future pandemic pathogens. The company secures venture capital funding to advance its research. Its technology aims to address emerging mutations in viruses.
Baseimmune secures $11.3 million in Series A funding to accelerate vaccine development. The round includes new investors MSD Global Health Innovation Fund and IQ Capital, alongside existing backers. The company focuses on improving vaccine efficacy and speeding up production timelines.
